KBI BioPharma

Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Comera Life Sciences is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient to produce.

Elion Labs, a contract services organization founded to serve the analytical development and product characterization needs of the biopharmaceutical industry. Elion offers a variety of services, including analytical method development, qualification and validation; analytical characterization testing of biologics; formulation development; training in highly specialized analytical techniques; comprehensive data analysis including visualization and interpretation of complex data sets; technical and regulatory writing; and technical consulting. Elion is committed to providing services with unmatched professionalism, quality, and speed.

GlycoSeLect specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs), enhanced tools for the analysis and selective purification of glycosylated biomolecules. RPLs have a broad spectrum of applications across the life sciences in: - Basic R&D – Glycobiology & Glycoproteomics. - Biomarker Discover & Biomedical Diagnostics. - The Biopharmaceutical Industry. - Vaccines - Cosmetics GlycoSeLect's Recombinant Prokaryotic Lectins (RPLs) present significant advantages over existing commercially available lectins products including: - Simplified, rapid & cost effective production through recombinant expression in Escherichia coli. - High purity & consistent performance. - Genetically enhanced glycan binding properties (specificity & affinity). - Scalable production facilitating utilization for large scale applications.

Alliance Protein Laboratories is a contract research and consulting firm specializing in biophysical analysis. It offers a broad range of biophysical characterization services, contract purification services (research scale), and consulting services.

Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that address rare genetic diseases.